FIELD: biotechnology.
SUBSTANCE: disclosed are: the use of an anti-interleukin-6 receptor (IL-6R) antibody in the treatment of rheumatoid arthritis (RA) in a subject, wherein the subject is administered from about 150 mg to about 200 mg of the antibody once every two weeks, where the IL-6R antibody comprises a heavy chain variable region comprising a sequence under SEQ ID NO: 1, and a light chain variable region comprising a sequence under SEQ ID NO: 2, and the antibody is administered subcutaneously, as well as a method of treating rheumatoid arthritis (RA) in a subject, comprising administering an antibody which specifically binds to a human interleukin-6 receptor (IL-6R) to a subject suffering from RA.
EFFECT: invention can be used to treat rheumatoid arthritis of a subject.
34 cl, 8 dwg, 6 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| COMPOSITIONS CONTAINING ANTIBODIES TO IL6R FOR TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF THEIR USE | 2016 |
|
RU2747193C2 |
| METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH ANTIBODIES WHICH BIND TO THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2013 |
|
RU2718751C2 |
| ANTIBODIES, THEIR APPLICATION AND METHODS OF APPLICATION | 2016 |
|
RU2725221C2 |
| METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH ADMINISTRATION OF IL-4R ANTAGONIST | 2013 |
|
RU2801531C2 |
| THERAPY MONITORING IN TREATMENT WITH BINDING AGENT AGAINST ADRENOMEDULLIN (ADM) | 2018 |
|
RU2776811C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| DOSES AND ADMINISTRATION OF ANTIBODIES AGAINST C5 FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) | 2020 |
|
RU2822664C2 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
